Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Motyl

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Experimental Parasitology|October 1, 1979
Plasmodium falciparum: loss of knobs on the infected erythrocyte surface after long-term cultivationS G Langreth, R T Reese, M R Motyl, et al.
Polskie Archiwum Medycyny Wewnetrznej|March 31, 2000
[Fabry's disease--late diagnosis in men with chronic nephropathy and skin changes]W Wegrzyn, A Undas, R Motyl, et al.
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)Michael A Pfaller, Shawn A Messer, Mary R Motyl, et al.
Journal of the Pediatric Infectious Diseases Society|June 15, 2020
In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|July 28, 2019
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017Sibylle H Lob, Daryl J Hoban, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|June 2, 2018
Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016Sibylle H Lob, Daryl J Hoban, Katherine Young, et al.
Diagnostic Microbiology and Infectious Disease|June 9, 2019
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|August 3, 2018
Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2012
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methodsMichael A Pfaller, Shawn A Messer, Mary R Motyl, et al.
BMC Microbiology|March 7, 2021
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Experimental Parasitology|October 1, 1979
Plasmodium falciparum: loss of knobs on the infected erythrocyte surface after long-term cultivationS G Langreth, R T Reese, M R Motyl, et al.
Polskie Archiwum Medycyny Wewnetrznej|March 31, 2000
[Fabry's disease--late diagnosis in men with chronic nephropathy and skin changes]W Wegrzyn, A Undas, R Motyl, et al.
The Journal of Antimicrobial Chemotherapy|November 30, 2012
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)Michael A Pfaller, Shawn A Messer, Mary R Motyl, et al.
Journal of the Pediatric Infectious Diseases Society|June 15, 2020
In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients-Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015-2017James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|July 28, 2019
Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017Sibylle H Lob, Daryl J Hoban, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|June 2, 2018
Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016Sibylle H Lob, Daryl J Hoban, Katherine Young, et al.
Diagnostic Microbiology and Infectious Disease|June 9, 2019
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Journal of Global Antimicrobial Resistance|August 3, 2018
Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Antimicrobial Agents and Chemotherapy|December 12, 2012
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methodsMichael A Pfaller, Shawn A Messer, Mary R Motyl, et al.
BMC Microbiology|March 7, 2021
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019James A Karlowsky, Sibylle H Lob, Katherine Young, et al.
Pageof 8